Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Neurogenic Orthostatic Hypotension in Parkinson's Disease”

10 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 10 of 10 results

Large-scale testing (Phase 3)Ended earlyNCT04095793
What this trial is testing

Phase 3 Open-Label Extension Study of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure

Who this might be right for
Symptomatic Neurogenic Orthostatic Hypotension
Theravance Biopharma 110
Post-approval studies (Phase 4)Study completedNCT03229174
What this trial is testing

Brain Perfusion & Oxygenation in Parkinson's Disease With NOH

Who this might be right for
Parkinson DiseaseNeurogenic Orthostatic Hypotension
William Ondo, MD 17
Not applicableUnknownNCT03343574
What this trial is testing

Cardiovascular Effects of Exercise in Patients With Parkinson's Disease

Who this might be right for
Parkinson DiseaseOrthostatic Hypotension
Faizan Ahmed 300
Testing effectiveness (Phase 2)Study completedNCT01971008
What this trial is testing

Abdominal Binder to Treat Orthostatic Hypotension (OH) in Parkinson's Disease (PD)

Who this might be right for
Parkinson's DiseaseNeurogenic Orthostatic Hypotension in Parkinson's Disease
Medical University Innsbruck 15
Large-scale testing (Phase 3)Study completedNCT03750552
What this trial is testing

Clinical Effect of Ampreloxetine (TD-9855) for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure

Who this might be right for
Symptomatic Neurogenic Orthostatic Hypotension
Theravance Biopharma 195
Post-approval studies (Phase 4)Study completedNCT02586623
What this trial is testing

Sustained Effect of Droxidopa in Symptomatic Neurogenic Orthostatic Hypotension

Who this might be right for
Symptomatic Neurogenic Orthostatic Hypotension
H. Lundbeck A/S 453
Testing effectiveness (Phase 2)UnknownNCT00758849
What this trial is testing

Fipamezole in Neurogenic Orthostatic Hypotension

Who this might be right for
Symptomatic Neurogenic Orthostatic Hypotension (NOH)Parkinson's DiseaseMultiple System Atrophy
Juvantia Pharma Ltd 24
Not applicableStudy completedNCT01316666
What this trial is testing

Norepinephrine Transporter Blockade as a Pathological Biomarker in Neurogenic Orthostatic Hypotension

Who this might be right for
Orthostatic HypotensionPure Autonomic FailureMultiple System Atrophy+1 more
Vanderbilt University Medical Center 50
Large-scale testing (Phase 3)Ended earlyNCT03829657
What this trial is testing

Phase 3 Clinical Effect Durability of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure

Who this might be right for
Symptomatic Neurogenic Orthostatic HypotensionMSAParkinson's Disease (PD)+1 more
Theravance Biopharma 203
Large-scale testing (Phase 3)Study completedNCT01176240
What this trial is testing

A Two Part Study (306A/306B) to Assess Droxidopa in Treatment of NOH in Patients With Parkinson's Disease

Who this might be right for
Orthostatic HypotensionParkinson's Disease
Chelsea Therapeutics 225